Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop
Date:4/28/2011

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in Paris, France.

"The data we are accumulating for carfilzomib continues to support its potential as an important new treatment option for patients with multiple myeloma.  Data from several studies will be presented at the upcoming IMW meeting, including interim data in newly diagnosed patients from a Multiple Myeloma Research Consortium study being led by Dr. Andrzej Jakubowiak at the University of Michigan Comprehensive Cancer Center that is evaluating carfilzomib in combination with a standard therapy," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "Onyx is committed to bringing this promising therapy to patients as quickly as possible and remains on track for filing a new drug application with the U.S. Food and Drug Administration as early as mid-year under the accelerated approval process.  We are also actively enrolling patients in the Phase 3 FOCUS trial for the treatment of patients with relapsed and refractory myeloma to support a filing with the European Medicines Agency, as well as, in the Phase 3 ASPIRE trial in relapsed multiple myeloma."

Carfilzomib data highlights include:

Carfilzomib and other new proteasome inhibitors: Clinical data

  • Andrzej Jakubowiak, M.D., Ph.D., University of Michigan Comprehensive Cancer Center, USA
  • Thursday, May 5, 2011, 14:19 – 14:31
  • Oral Session Name: Plenary Session I: New Drugs and Therapeutic Approaches

Results of PX-171
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2011 Financial Results on May 5, 2011
2. OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Idenix Pharmaceuticals Reports First Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
6. Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress
7. Reportlinker Adds The Outlook for Pharmaceuticals in Latin America
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
9. HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
10. Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
11. Cumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015 Roche (SIX: RO, ROG; OTCQX: ... EGFR Mutation Test v2 for Premarket Approval (PMA) ... as a companion diagnostic test for AZD9291, an ... patients with an acquired resistant mutation.  ... have adenocarcinoma with tumor containing an EGFR sensitizing ...
(Date:7/29/2015)... Calif. , July 29, 2015  UBM Canon ... San Diego Marriott Marquis & Marina on September 1-2, ... device industry. A highlight of the Business Development track ... Backing from Different Types of Investors, featuring Renee ... Johnson Development Corporation; Brent Ahrens , Partner, Canaan ...
(Date:7/29/2015)... Calif. and CAMBRIDGE, Mass. ... Inc. (NASDAQ: ISIS ), the leader in ... subsidiary, announced today that The New England ... a Phase 2 clinical study evaluating volanesorsen (formerly ... to severely high triglycerides. This publication follows the ...
Breaking Medicine Technology:Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 2Roche submits filing to FDA for companion diagnostic for non-small cell lung cancer drug therapy 3MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 2Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 3Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 4Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 5Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 6Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine 7
... Aug. 24 Physicians at Southern,Health have started a ... a new strategy for defeating hepatitis C viral infection, ... Implicit Bioscience,s drug, oglufanide disodium, which works as ... by intranasal,administration to patients with chronic hepatitis C viral ...
... Fund Continued Rapid Growth and Innovation, AUDUBON, Pa., ... implant manufacturer in the world, today announced,the closing of ... led the round and was joined by AIG SunAmerica ... Securities, LLC acted,as sole placement agent. The Series ...
Cached Medicine Technology:Drug in New Hepatitis C Clinical Trial 2Globus Medical Raises $110 Million in Series E Financing Round 2
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay Today Online ... to fund the state’s large prison system, which has amassed largely enough throughout the ... incarceration. In light of President Obama’s recent reduction of non violent drug offender’s prison ...
(Date:7/30/2015)... ... , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers comprehensive ... as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with decades ... around the world. , “Like treatment of any other disease or condition, making the ...
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... , ... Author Dr. Raul Llanos seeks to empower readers to ... book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and Abundance ” (published ... responsibility for ourselves, we can create better realities.” His book illustrates the possibilities of ...
(Date:7/30/2015)... ... , ... After a three year trial designed to study the efficiency and ... “bionic eye,” researchers have determined the trial to be a success, and are recommending ... affected by complete vision loss as a result of Retinitis pigmentosa. The results of ...
Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... common cancer drug imatinib (Gleevec), researchers have eliminated morphine ... the effectiveness of chronic pain management in patients, according ... Cancer Center. Narcotics such as morphine are a ... the pain-relieving effects of these drugs can develop, requiring ...
... caused by an erosion of the protective caps on chromosomes, ... allows malignant cells to evade destruction and acquire more deadly ... journal Cell . In a strain of ... through this two-step process developed lethal cancer and 25 percent ...
... A Cedars-Sinai research scientist has been awarded two ... prestigious Research Project Grant from the National Institutes of ... Terrence Town, PhD, is studying drugs that ... amyloid plaques that build up in the brain and ...
... HealthDay Reporter , MONDAY, Feb. 20 (HealthDay News) -- Alcohol ... new national survey reveals. The online, anonymous poll indicated ... abuse or dependence: nearly 14 percent of male surgeons and ... 8 percent to 12 percent figure typically cited for alcohol ...
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... Alzheimer,s disease drugs now being tested in clinical trials ... Northwestern Medicine research. A study with mice suggests the ... to be miswired and interfering with their ability to ... the scientist whose original research led to the drug ...
Cached Medicine News:Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 3Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 3Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 4Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Alzheimer's drugs may have adverse side effects 2
... The full color LCD ... familiar joystick controls, enable any ... make quick and accurate measurements.,Measurement ... the color screen, and results ...
... Patients who need punctal ... dry eye relief. They also ... be as comfortable and as ... why Alcon punctal plugs are ...
... to diagnostic images and reports, the powerful ... scaled to meet the needs of virtually ... Web PACS system allows clinicians, referring physicians, ... view images and information on-site or at ...
... SonoAce 9900 is a ... ultrasound system, with an ... DICOM compatible, designed for ... imaging, obstetrics, gynecology, perinatology, ...
Medicine Products: